ANALYSIS OF AGOMELATINE TREATMENT WITH DEPRESSIVE SYMPTOMS

Objective: Agomelatine is a new mechanism of antidepressants, which is approved by Taiwan Food and Drug Administration and available in Taiwan.Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. The structuresof agomelatine are similar to melatonin with not only the effects to maintain depression symptoms but also can help patients who have insomnia.Methods: This is a retrospective study. In a mental hospital in Taoyuan, we analyzed the prescriptions of the outpatients who were prescribedagomelatine to realize the effects of agomelatine and whether the prescriptions were prescribed appropriately.Results: Catastrophic illnesses were found to be associated with significantly used multiple hypnotics (χ2 =22.02, p<0.001). When patients’ ageincreased by 1 year, multiple hypnotics used increased by 1.013 times (Exp(B)=1.013, p<0.01). Catastrophic illnesses were found to be associatedwith significantly used augmentation with other antidepressants (χ2=54.07, p<0.001).Conclusions: Doctors should be evaluating the benefits and risks when they prescribe a medicine to patients, and they should be written in medicalrecord. This study is the hope to provide relevant units as a reference for formulating health policies.